Covered recipient · General Payments record
FATIMA ALAO
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$3,781.19
- Reported across 289 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $537.90 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $194.25 | 18 |
| EISAI INC. | $74.66 | 3 |
| Lundbeck LLC | $66.31 | 3 |
| Lilly USA, LLC | $40.46 | 2 |
| JAZZ PHARMACEUTICALS INC. | $32.81 | 1 |
| UCB, Inc. | $32.39 | 2 |
| Biogen, Inc. | $28.17 | 2 |
| GENZYME CORPORATION | $18.60 | 1 |
| Ceribell, Inc. | $17.41 | 1 |
| SK Life Science, Inc. | $16.75 | 1 |
| Neurelis, Inc. | $16.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.59 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196288 | CMS |
| ABBVIE INC. | $9.24 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196290 | CMS |
| ABBVIE INC. | $8.14 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196292 | CMS |
| ABBVIE INC. | $10.76 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196294 | CMS |
| ABBVIE INC. | $8.35 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196296 | CMS |
| ABBVIE INC. | $6.41 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196298 | CMS |
| ABBVIE INC. | $15.11 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196300 | CMS |
| ABBVIE INC. | $8.16 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196302 | CMS |
| ABBVIE INC. | $9.79 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196304 | CMS |
| ABBVIE INC. | $10.75 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196306 | CMS |
| ABBVIE INC. | $20.81 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196308 | CMS |
| ABBVIE INC. | $8.02 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196310 | CMS |
| ABBVIE INC. | $2.39 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196312 | CMS |
| ABBVIE INC. | $8.12 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196314 | CMS |
| ABBVIE INC. | $9.63 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196316 | CMS |
| ABBVIE INC. | $15.81 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196318 | CMS |
| ABBVIE INC. | $11.28 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196320 | CMS |
| ABBVIE INC. | $14.89 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103196322 | CMS |
| Biogen, Inc. | $13.73 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104833967 | CMS |
| Biogen, Inc. | $14.44 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104833969 | CMS |
| Ceribell, Inc. | $17.41 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153955841 | CMS |
| Eisai Inc. | $17.83 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110745340 | CMS |
| Eisai Inc. | $19.87 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110745338 | CMS |
| Eisai Inc. | $36.96 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110745342 | CMS |
| GENZYME CORPORATION | $18.60 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139830706 | CMS |
| JAZZ PHARMACEUTICALS INC. | $32.81 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150228265 | CMS |
| Lilly USA, LLC | $22.62 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134972471 | CMS |
| Lilly USA, LLC | $17.84 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134964527 | CMS |
| Lundbeck LLC | $21.80 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145890197 | CMS |
| Lundbeck LLC | $28.62 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145890199 | CMS |
| Lundbeck LLC | $15.89 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145890201 | CMS |
| Neurelis, Inc. | $16.09 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145630574 | CMS |
| SK Life Science, Inc. | $16.75 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154151979 | CMS |
| UCB, Inc. | $18.87 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143386422 | CMS |
| UCB, Inc. | $13.52 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143386426 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.